Skip to main content

Table 1 Descriptive statistics of the treatment groups at baseline

From: Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy

  P Deferiprone group (n = 39) Combined group (n = 51) Deferoxamine group (n = 74) P
Age (yrs) 0.136 31.5 ± 5.3 29.6 ± 6.5 32.7 ± 8.5 0.032
Male (%) 0.022 69.2% 45.1% 48.6% 0.719
Chel. starting age (yrs) 0.499 5.1 ± 5.1 4.3 ± 4.1 6.6 ± 4.9 0.030
Pre-transfusion Hb (g/dl) 0.379 9.5 ± 0.7 9.6 ± 0.5 9.7 ± 0.6 0.213
Ferritin (ng/l) 0.001 941 ± 1541 1814 ± 1033 1093 ± 1256 0.001
Global Heart (ms) 0.0001 31.3 ± 11.3 21.5 ± 12.9 28.5 ± 10.7 0.002
MRI CIC (mg/g dry w) 0.001 0.94 ± 0.79 2.15 ± 2.38 1.03 ± 0.79 0.001
N seg. with T2* < 20 ms 0.001 3.9 ± 6.2 8.7± 7.0 4.4 ± 5.9 0.001
Mid septum T2* (ms) 0.0001 34.0 ± 13.0 22.3 ± 14.3 30.6 ± 12.8 0.001
LV EF (%) 0.643 61.8 ± 9.0 62.6 ± 7.0 61.6 ± 6.0 0.364
LV EDVI (ml/m2) 0.069 91.9 ± 20.0 84.7 ± 17.6 89.6 ± 20.2 0.164
RV EF (%) 0.336 59.9 ± 8.8 61.6 ± 6.8 60.9 ± 7.0 0.587
RV EDVI (ml/m2) 0.126 89.7 ± 19.9 83.8 ± 16.4 88.1 ± 20.5 0.210
Liver T2* (ms) 0.110 8.9 ± 8.0 6.3 ± 6.8 11.0 ± 7.5 0.0001
MRI LIC (mg/g dry weight) 0.330 8.2 ± 8.9 10.3 ± 10.1 5.3 ± 6.2 0.003
  1. All values are quoted as mean ± SD. The P-values concern the comparison between combined and deferiprone groups and between combined and deferoxamine groups.